Drug Type Small molecule drug |
Synonyms EYP-001, EYP-001A, EYP001 + [3] |
Target |
Mechanism FXR agonists(Bile acid receptor FXR agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization ENYO Pharma SAStartup |
Inactive Organization |
Drug Highest PhasePhase 2 |
First Approval Date- |
RegulationOrphan Drug (US), Orphan Drug (EU) |
Molecular FormulaC19H15Cl3N2O5S |
InChIKeyXLGQSYUNOIJBNR-UHFFFAOYSA-N |
CAS Registry1192171-69-9 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Nephritis, Hereditary | Phase 2 | US | ENYO Pharma SAStartup | 06 Jun 2024 |
Nephritis, Hereditary | Phase 2 | FR | ENYO Pharma SAStartup | 06 Jun 2024 |
Nephritis, Hereditary | Phase 2 | DE | ENYO Pharma SAStartup | 06 Jun 2024 |
Nephritis, Hereditary | Phase 2 | ES | ENYO Pharma SAStartup | 06 Jun 2024 |
Hepatitis B, Chronic | Phase 2 | AU | ENYO Pharma SAStartup | 12 May 2020 |
Hepatitis B, Chronic | Phase 2 | HK | ENYO Pharma SAStartup | 12 May 2020 |
Hepatitis B, Chronic | Phase 2 | PL | ENYO Pharma SAStartup | 12 May 2020 |
Hepatitis B, Chronic | Phase 2 | KR | ENYO Pharma SAStartup | 12 May 2020 |
Nonalcoholic Steatohepatitis | Phase 2 | US | ENYO Pharma SAStartup | 30 Jan 2019 |
Nonalcoholic Steatohepatitis | Phase 2 | BE | ENYO Pharma SAStartup | 30 Jan 2019 |
Phase 2 | 120 | Placebo (Placebo Part B) | ekjilpdflf(nzlbvwtmmt) = jmfbjzwtjk pbermrppmp (koxzlmiqef, zjzdqdngxr - yrnplvcnhw) View more | - | 06 May 2023 | ||
(Vonafexor 100 mg QD Part B) | ekjilpdflf(nzlbvwtmmt) = kbgouoawtd pbermrppmp (koxzlmiqef, amsuzsbozg - fqpiplpzqi) View more | ||||||
Phase 2 | 26 | Nucleotide analogue (Entecavir or Tenofovir Disoproxil)+EYP001a (Experimental Arm) | gcohnzbmkp(lugreccoru) = birrvuzdjm vhtlgtpwdh (jxziurgrhc, gjiuadknoe - cextwmhtqf) View more | - | 12 Oct 2022 | ||
Nucleotide analogue (Entecavir or Tenofovir Disoproxil) (Control Arm) | gcohnzbmkp(lugreccoru) = iacdaijrwj vhtlgtpwdh (jxziurgrhc, jnoojjzxvs - lcxmsierld) View more | ||||||
Phase 2 | 20 | anzxgzilxa(okwqahiyry) = krjqtcetip ldkcbeegmf (oqtqumloga ) | Positive | 30 Jul 2021 | |||
Peginterferon alfa-2a+Vonafexor | anzxgzilxa(okwqahiyry) = hbkmwbdtmq ldkcbeegmf (oqtqumloga ) |